Mounjaro sales double this year as obesity drug boom prevails, says maker
7 Articles
7 Articles
In the age of the new anti-obesity drugs, capable of leading to losses greater than 15% or 20% of the initial weight, the impression is that the balance pointer is the great responsible for revealing the success of the treatment.
The US laboratory obtained a net profit of 7,095 million dollars in the second quarter of 2026, representing an annual advance of 25% thanks to the growth of the sales of Mounjaro and Zepbound, according to the multinational, which has revised upwards its forecast of revenues for the whole year.
The pharmaceutical companies Eli Lilly, owner of the Mounjaro, and Novo Nordisk, holder of the Ozempic, have raised their plans for the whole year, driven by the triggering of demand for medicines for obesity and diabetes, but the Danish pharmaceutical companies have retreated to the concern of investors with their strong dependence on their treatment campe the sales. Read more (08/05/2026
Coverage Details
Bias Distribution
- 80% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
